Mineralys Therapeutics In... (MLYS)
NASDAQ: MLYS
· Real-Time Price · USD
14.51
0.38 (2.69%)
At close: Aug 15, 2025, 3:59 PM
14.52
0.10%
After-hours: Aug 15, 2025, 04:20 PM EDT
Mineralys Therapeutics Balance Sheet Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q1 2022 | Q4 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Mar 31, 2022 | Dec 31, 2021 |
Cash & Equivalents | 101.79M | 165.01M | 114.09M | 97.27M | 67.86M | 90.42M | 49.3M | 86.3M | 101.14M | 138.25M | 87.7M | 48.95M | -10.61M | 10.61M |
Short-Term Investments | n/a | 178.02M | 84.1M | 166.33M | 243.26M | 248.15M | 187.26M | 167.46M | 159.96M | 132.39M | 22.41M | 72M | 21.22M | n/a |
Long-Term Investments | n/a | n/a | n/a | n/a | n/a | n/a | 2.48M | 12.13M | 21.68M | 31.12M | n/a | n/a | n/a | n/a |
Other Long-Term Assets | 433K | 397K | 499K | 452K | 449K | 379K | 51K | 51K | 51K | 39K | 4.33M | 564K | -10.61M | 3K |
Receivables | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Inventory | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Current Assets | 233.48M | 11.48M | 7.16M | 4.13M | 6.89M | 8.25M | 12.54M | n/a | 8.39M | 4.63M | 2.7M | n/a | n/a | n/a |
Total Current Assets | 335.27M | 354.51M | 205.35M | 267.73M | 318M | 346.82M | 249.1M | 265.38M | 269.49M | 275.27M | 110.11M | 121.89M | 10.61M | 11.12M |
Property-Plant & Equipment | 22K | 38K | 53K | 69K | 42K | 51K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Goodwill & Intangibles | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Total Long-Term Assets | 455K | 435K | 552K | 521K | 491K | 430K | 2.53M | 12.18M | 21.73M | 31.16M | 4.33M | 564K | -10.61M | 3K |
Total Assets | 335.72M | 354.94M | 205.9M | 268.25M | 318.49M | 347.25M | 251.64M | 277.56M | 291.22M | 306.44M | 114.44M | 122.45M | n/a | 11.13M |
Account Payables | 3.16M | 373K | 479K | 3.11M | 1.71M | 4.26M | 601K | 5.57M | 2.2M | 2.39M | 1.91M | 2.56M | n/a | 763K |
Deferred Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Short-Term Debt | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Current Liabilities | 22.17M | 1.15M | 3.58M | n/a | n/a | n/a | n/a | 6.75M | n/a | 381K | n/a | n/a | n/a | n/a |
Total Current Liabilities | 22.17M | 13.39M | 14.65M | 31.32M | 28.4M | 19.2M | 10.48M | 13.54M | 6.21M | 10.56M | 8.07M | 7.22M | n/a | 5.05M |
Long-Term Debt | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Long-Term Liabilities | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 158.64M | n/a | n/a |
Total Long-Term Liabilities | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 158.64M | 158.64M | n/a | 29M |
Total Liabilities | 22.17M | 13.39M | 14.65M | 31.32M | 28.4M | 19.2M | 10.48M | 13.54M | 6.21M | 10.56M | 166.71M | 165.86M | n/a | 34.05M |
Total Debt | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock | 6K | 6K | 5K | 5K | 5K | 5K | 4K | 4K | 4K | 4K | 1K | 1K | n/a | 1K |
Retained Earnings | -388M | -344.73M | -302.52M | -253.57M | -197.23M | -156.22M | -124.71M | -100.32M | -77.56M | -65.42M | -52.81M | -43.74M | n/a | -23.01M |
Comprehensive Income | n/a | n/a | n/a | n/a | n/a | n/a | -251.64M | -277.56M | -0.00 | n/a | -158.64M | n/a | -22.93M | -0.00 |
Shareholders Equity | 313.55M | 341.56M | 191.26M | 236.93M | 290.1M | 328.05M | 241.15M | 264.01M | 285.01M | 295.88M | -52.27M | -43.41M | 6.07M | -22.93M |
Total Investments | n/a | 178.02M | 84.1M | 166.33M | 243.26M | 248.15M | 189.75M | 179.59M | 181.63M | 163.51M | 22.41M | 72M | 21.22M | n/a |